ArticleCurrent drug targets2026
Antimicrobial Potential of Commercially Produced Citronella Oil: An
Article in Current drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAntimicrobial resistance poses a significant global health threat in the 21st century. The COVID-19 pandemic, caused by SARS-CoV-2, has further emphasized the need for novel and effective alternative therapeutics, especially from natural sources. Despite the known bioactivity of citronella oil, its potential as a broad-spectrum antimicrobial and antiviral agent remains underexplored. This study aimed to evaluate the antibacterial, antifungal, and antiviral potential of commercially produced citronella oil using in vitro and in silico approaches.
methodsThe chemical constituents of citronella oil were identified using gas chromatographymass spectrometry (GC-MS). Antibacterial activity was assessed using the disk diffusion method, while antifungal efficacy was evaluated via the poison plate method. In silico techniques, including molecular docking, ADMET profiling, density functional theory, molecular dynamics simulation, principal component analysis, and dynamic cross-correlation mapping, were used to predict antiviral activity against the SARS-CoV-2 main protease (Mpro).
resultsGC-MS identified 30 compounds in citronella oil. Antibacterial assays demonstrated notable inhibition against DISCUSSION: The results show that commercially available citronella oil has strong antifungal properties and moderate antibacterial properties. This suggests that it could be a natural broadspectrum antimicrobial agent. Furthermore,
conclusionThis study presents the first report on the therapeutic potential of commercially produced citronella oil from Bangladesh as a dual-purpose antimicrobial and antiviral agent. The antifungal potential of citronella oil surpassed its antibacterial efficacy against the tested strains, and CID-91697 is recommended as a promising lead compound against SARS-CoV-2 according to the outcomes of in silico studies. These findings support further experimental and clinical validation of citronella oil as a sustainable, natural alternative for combating infectious diseases.
Indexed as
Identifiers
41486995What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.